Mikhail Blagosklonny is an oncologist who conducts researches on health issues relating to aging and cancer. Oncology is that discipline of medicine that deals with the study of prevention, diagnosis, and prevention of cancer diseases. Blagosklonny has researched on biogerontology and anti-aging drugs.
Aging is the persistence of growth stimulated by beckoning pathways such as Target of Rapamycin, TOR. Most people believe that it is caused by a failure of maintenance which further causes more molecular injury. However, aging is not caused by the buildup of microscopic damage or by accidental injury of any kind in the body. Mikhail Blagosklonny articulated a hypothesis about the role of TOR signaling in aging. Aging can be treated by use of rapamycin together with other rapalogs as predicted by the TOR-centric model. Pathways that trigger growth in the body of humans operate on inertia even when completion of advancement growth has occurred. The TOR changes quiescent cells into senescent cells without involving any form of molecular impairment. The TOR pathway links to age-related diseases. It is the same path that stimulates the developmental growth that leads to aging and its related diseases. View Mikhail’s profile on Google Scholar
Over-simulation is known to cause growth in functions such as glycogenesis by liver cells, secretion by fibroblasts, aggregation by Platelets, inflammation by neutrophils, bone resorption by osteoclasts and phagocytosis by macrophages. However, these functions get lost in terminal aging. The loss of function results from the initial hyperfunction. Cellular hyperfunction is a major sign of aging. Sometimes the intake of hypertensive drugs can slow down the pathways signaling the hyperfunction and in the eventuality, end up preventing other age-related diseases. Examples of these drugs include angiotensin 2 and inhibitors of beta-adrenergic. Metformin is another drug which obstructs the TOR pathway. This results in prevention of premature menopause in women, lengthened life span, and reduced chances of cancers all which are related to aging.
Loss of homeostasis or the ARD, age-related diseases reduces the lifespan of humans in protected environments. Fortunately, postponement of this condition is possible by genetic manipulation, drugs and calorie restriction which deactivate the mTOR pathway.
The approval of Rapamycin also known as Sirolimus for clinical use occurred in 2006, and its use began in the same year. This drug is recommended for treating cancer, but recently it has been identified as a life extension medicine. Aging comes with several diseases, and this anti-aging drug has been approved as safe for use as a daily dose since it is non-toxic. The drug also contains bone-sparing and anti-tumor imitating side effects. The use of rapamycin not only treats aging but also extends the human lifespan and health span by preventing them from diseases. Rapamycin is used to treat autoimmunity, osteoporosis, cancer, Alzheimer, cardiovascular illnesses and metabolic disorders. Rapamycin is the most useful anti-aging drug as it not only treats the mentioned diseases but rather boosts the immunity. In fact, it is described to revive the immune system from old type to that of an infant. The drug works by removing hyper-immunity and therefore does not suppress the immunity of patients.